Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
454.69
+0.95 (+0.21%)
Streaming Delayed Price
Updated: 12:33 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
69
70
Next >
Where Will Vertex Pharmaceuticals Be in 5 Years
↗
November 27, 2025
Prediction: Vertex will be much larger by the end of the decade.
Via
The Motley Fool
2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon
↗
November 23, 2025
If you're investing for the next 30 years, don't overlook these top stocks.
Via
The Motley Fool
Topics
Intellectual Property
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why
November 21, 2025
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 2.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.
Via
StockStory
Topics
Artificial Intelligence
Economy
Supply Chain
2 Inflation-Proof Growth Stocks That Could Outperform the Market
↗
November 20, 2025
Inflation should have a minimal impact on these companies' financial results. And they also boast excellent growth prospects.
Via
The Motley Fool
Topics
Economy
Intellectual Property
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Case for Value Investors
↗
November 20, 2025
Vertex Pharmaceuticals (VRTX) presents a strong value investment case with a low P/E ratio, robust profitability, a healthy debt-free balance sheet, and accelerating earnings growth.
Via
Chartmill
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results
November 19, 2025
Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of...
Via
MarketMinute
Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3
November 19, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today
↗
November 19, 2025
Via
Benzinga
1 Cash-Heavy Stock with Solid Fundamentals and 2 We Ignore
November 19, 2025
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...
Via
StockStory
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
↗
November 19, 2025
These stocks both have advanced in the double-digits in recent months.
Via
The Motley Fool
Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support?
↗
November 17, 2025
Via
Benzinga
1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November
↗
November 17, 2025
It's a good idea to go against the current market sentiment on this one.
Via
The Motley Fool
The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market
November 14, 2025
The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 14, 2025
Via
Benzinga
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
November 12, 2025
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Via
StockStory
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top Affordable Growth Stock
↗
November 12, 2025
Vertex Pharmaceuticals offers strong growth, solid profits, and a healthy balance sheet, all at a reasonable valuation compared to its biotech peers.
Via
Chartmill
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
November 10, 2025
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call
November 10, 2025
Vertex Pharmaceuticals’ third quarter was marked by steady double-digit revenue growth, yet the market responded negatively as margin compression and operational investments weighed on sentiment....
Via
StockStory
Topics
Earnings
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
November 08, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
November 07, 2025
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...
Via
MarketMinute
Topics
Artificial Intelligence
Intellectual Property
Global Markets Brace for Inflation's Enduring Grip: A November 2025 Outlook
November 07, 2025
As November 2025 unfolds, global financial markets find themselves in a complex and challenging environment, bracing for the enduring grip of inflation. Despite some signs of moderating headline...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Economy
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included
↗
November 07, 2025
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.
Via
Benzinga
2 Nasdaq 100 Stocks with Competitive Advantages and 1 Facing Challenges
November 05, 2025
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that...
Via
StockStory
Palantir Weighs On Wall Street, Bitcoin Slumps 5%: What's Moving Markets Tuesday?
↗
November 04, 2025
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date...
Via
Benzinga
VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook
November 04, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was...
Via
StockStory
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations
November 03, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was...
Via
StockStory
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book
↗
November 03, 2025
Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.
Via
Investor's Business Daily
Vertex Reports Third Quarter 2025 Financial Results
November 03, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
↗
November 03, 2025
Via
Benzinga
Nvidia, Amazon Extend Rally, Bitcoin Sinks To $107,000: What's Moving Markets Monday?
↗
November 03, 2025
Wall Street opened the week on a mixed note on Monday.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
69
70
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
